Personalis (PSNL) and Tempus AI (TEM) said Monday they have expanded their collaboration to the biopharma industry.
Tempus is the exclusive commercial diagnostic partner for Personalis' NeXT Personal Dx minimal residual disease product for broad patient adoption in breast and lung cancers, as well as for immunotherapy monitoring across all solid tumors.
The expanded collaboration allows Tempus to offer the product to pharmaceutical and biotech customers who are looking to bundle minimal residual disease testing with other Tempus offerings in a given study, the companies said.
Price: 3.90, Change: +0.08, Percent Change: +2.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。